64. Thrombotic thrombocytopenic purpura
74 clinical trials,   76 drugs   (DrugBank: 19 drugs),   15 drug target genes,   57 drug target pathways

Searched query = "Thrombotic thrombocytopenic purpura", "TTP", "Upshaw-Schulman syndrome", "USS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-000858-18-AT
(EUCTR)
20/03/201805/12/2017A Phase 3, randomized, controlled study of severe congenital thrombotic thrombocytopenic purpura, with Bax 930.A phase 3, prospective, randomized, controlled, open-label, multicenter, 2-period crossover study with a single arm continuation evaluating the safety and efficacy of BAX 930 (rADAMTS13) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP, Upshaw-Schulman Syndrome [USS], hereditary thrombotic thrombocytopenic purpura [hTTP]) - A phase 3, randomized, controlled study of prophylactic and on-demand treatment of cTTP with BAX 930 severe congenital thrombotic thrombocytopenic purpura(cTTP, Upshaw-Schulman Syndrome [USS], hereditary thromboticthrombocytopenic purpura [hTTP])
MedDRA version: 20.0;Level: LLT;Classification code 10043562;Term: Thrombocytopenic purpura, thrombotic;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs 13
Product Code: BAX930 or SHP655
INN or Proposed INN: apadamtase alfa
Other descriptive name: Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs
Trade Name: Octaplas SD
Product Name: Octaplas®LG
INN or Proposed INN: Octaplas
Other descriptive name: Pooled Plasma (Human), Solvent/Detergent Treated
Product Name: Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs 13
Product Code: BAX930 or SHP655
INN or Proposed INN: apademtase alfa
Other descriptive name: Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1
Baxalta Innovations GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
68Phase 3United States;France;Canada;Poland;Spain;Austria;Germany;United Kingdom;Switzerland;Japan;Italy
2NCT03369314
(ClinicalTrials.gov)
March 2, 201830/11/2017Observational Study of the Use of octaplasLG®.Observational, Real-life Study of the Use of octaplasLG®.Thrombotic Thrombocytopenic PurpuraDrug: octaplasLG®OctapharmaNULLRecruitingN/AN/AAll100France;New Caledonia
3NCT01938404
(ClinicalTrials.gov)
June 6, 20172/9/2013Octaplas Adult TTP TrialPost-Marketing Requirement Study to Evaluate the Safety and Efficacy of Octaplas™ in Patients With Thrombotic Thrombocytopenic Purpura With Special Emphasis on Monitoring the Occurrence of Thromboembolic EventsThrombotic Thrombocytopenic PurpuraBiological: Octaplas;Drug: Standard PlasmaOctapharmaNULLTerminated18 YearsN/AAll1United States
4NCT01754545
(ClinicalTrials.gov)
September 201212/12/2012Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic PurpuraProphylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic PurpuraPurpura, Thrombotic ThrombocytopenicDrug: Octaplas infusion and placebo (group 1);Drug: Octaplas infusion and placebo (group 2)St. Olavs HospitalNorwegian University of Science and TechnologyWithdrawn18 Years65 YearsBoth0Phase 4Norway